Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Fda Inspections
  6. /
  7. Gland Pharma Limited, Units I+II Pashamylaram Site
FDA Inspection
•Gland Pharma Limited, Units I+II Pashamylaram Site•February 23, 2018

Gland Pharma Limited, Units I+II Pashamylaram Site – FDA Inspection, Feb 23, 2018

Record Details

This FDA Inspection record concerns Gland Pharma Limited, Units I+II Pashamylaram Site, with an inspection on February 23, 2018, issued by the Center for Drug Evaluation and Research, covering drugs.

Company
Gland Pharma Limited, Units I+II Pashamylaram Site
Inspection Date
February 23, 2018
Product Type
Drugs
Office
Center for Drug Evaluation and Research
People
  • Eileen A. Liu
  • Farhana Khan (FDA Associated Person)
View Company Profile

ID · 2a89c877-04b5-44c9-bda9-2d69a6bcbb57

Inspection Facts

Voluntary Action Indicated (VAI)

Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.

Inspection number
1043371
FDA center
Human Drugs
Project area
Drug Quality Assurance
Outcome
Form 483 issued

FDA Citations

4
  1. 21 CFR 211.25(a)Training , Education , Experience overall
  2. 21 CFR 211.198(a)Complaint Handling Procedure
  3. 21 CFR 211.113(b)Procedures for sterile drug products
  4. 21 CFR 211.110(b)In-process conformity - examination, sample testing

Full citation text and observation details available on the Dashboard.

Other FDA inspections of Gland Pharma Limited, Units I+II Pashamylaram Site

6
DateClassificationOfficeProject area
August 2, 2024Not classifiedOffice of Inspections and InvestigationsDrug Quality Assurance
August 26, 2023VAICenter for Devices and Radiological HealthCompliance: Devices
June 27, 2023VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
November 7, 2019VAICenter for Drug Evaluation and ResearchDrug Quality Assurance
May 29, 2018Not classifiedOffice of Inspections and Investigations
View all 6 other inspections on the company page
Other documents for Gland Pharma Limited, Units I+II Pashamylaram Site
  • FDA Inspection 1244660 - 2024-08-02
  • FDA Inspection 1216053 - 2023-08-26
  • FDA Inspection 1210478 - 2023-06-27
  • FDA Inspection 1109239 - 2019-11-07
  • FDA Inspection 1057719 - 2018-05-29

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Gland Pharma Limited, Units I+II Pashamylaram Site
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.